Farmas USA

bastardo y ademas tonto'los'cojones

Por el precio del que habla excluyo a la obvia que sería MDVN. Quizás podría ser ALXN al doble de lo que cotiza? BMY acaba de anunciar compra de una bio sueca pero muy pequeña.
Edito: o VRTX al doble de lo que cotiza también. Esque el bastardo está hablando de un solo Deal por valor de más de $60 B ??

O sus fuentes no eran muy fiables o era otra de sus bromitas... Yo creo que lo dejó en el aire para que la gente especulara y estuviera al tanto. Como dice framus, es que es muy tonto.

CEMP
PDUFA 26, 27 de diciembre.

Sus fuentes son 0 fiables. Quien le va a contar nada a este que lo twitea todo? Y tiene 0 reconocimiento en la industria.
Sobre CEMP:
The FDA accepts for review Cempra's (NASDAQ:CEMP) New Drug Applications (NDAs) seeking approval of intravenous and oral capsule formulations of Solithera (solithromycin) for the treatment of community-acquired bacterial pneumonia (CABP).
• Solithromycin is a next-generation antibiotic called a fluoroketolide, a member of a class of drugs that has shown effectiveness against drug-resistant bacteria because of their ability to bind to two sites on the bacterial ribosome. The FDA has designated it a Qualified Infectious Disease Product (QIDP) for Fast Track review. QIDP status provides for an additional five-year period of market exclusivity in the U.S., if approved.

Siguen las compras japonesas de células. TIG la presenté hace tiempo, aunque no sea carne de este hilo.

Takeda and TiGenix Enter into Licensing Agreement for Ex-U.S. rights to Cx601 for the Treatment of Complex Perianal Fistulas in Patients with Crohn's Disease

https://globenewswire.com/news-release/2016/07/05/853503/10163907/en/Takeda-and-TiGenix-Enter-into-Licensing-Agreement-for-Ex-U-S-rights-to-Cx601-for-the-Treatment-of-Complex-Perianal-Fistulas-in-Patients-with-Crohn-s-Disease.html

Sobre el congreso de células

5 big picture stem cell trends at #ISSCR2016

the most striking change from past ISSCR meetings was the relatively large focus on differentiation. While there was still lots of discussion of potency of stem cells and inherent stem cell properties, there was much more emphasis on mechanisms of commitment and differentiation.

I could be wrong, but I got the feeling that despite the continued excitement about IPS cells that this ISSCR annual meeting had less focus relatively speaking on them than past ones at least. There were more talks on ES cells and adult stem cells from what I saw.

CRISPR feels pretty standard. Almost everyone is excited about CRISPR-based gene editing, but at this meeting to me it felt like CRISPR was mostly only a side note. It’s a method to get at genetic events and molecular mechanisms, but it itself did not generate that much buzz.

http://www.ipscell.com/2016/06/big-picture-stem-cell-trends-at-isscr2016/

Progenics Pharmaceuticals Inc. (PGNX) Pre-Market Trading
$4.98 +0.55 +12.42%

5800 cromos

Bueno se cumplió la primera taza y su proyección, la segunda está en camino....
¿La cumplirá también?

Creo que dando al enlace de la respuesta se pueden ver los gráficos de hace un mes más o menos.

EXEL